Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash from Operations (2020 - 2025)

Treace Medical Concepts' Cash from Operations history spans 6 years, with the latest figure at 8026000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 90.78% year-over-year to 8026000.0; the TTM value through Dec 2025 reached 15970000.0, up 57.03%, while the annual FY2025 figure was 15970000.0, 57.03% up from the prior year.
  • Cash from Operations reached 8026000.0 in Q4 2025 per TMCI's latest filing, up from 9092000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4198000.0 in Q1 2025 to a low of 17259000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 6777650.0, with a median of 7365500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: plummeted 1710.25% in 2022, then soared 158.14% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 3793000.0 in 2021, then plummeted by 41.26% to 5358000.0 in 2022, then surged by 109.93% to 532000.0 in 2023, then tumbled by 890.79% to 4207000.0 in 2024, then tumbled by 90.78% to 8026000.0 in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Cash from Operations are 8026000.0 (Q4 2025), 9092000.0 (Q3 2025), and 3050000.0 (Q2 2025).